The prevalence of patients with EGFR-mutated and ALK-rearranged NSCLC in our cohort was low, so we were not able to draw any conclusions on the impact of these biomarkers on the prevalence and incidence of brain metastases and on the course of the disease. This evidence concerns the gene ALK and non-small cell lung carcinoma.